Buck study on Huntington's disease is named one of the best papers published by Journal of Biological Chemistry in 2014

Research by faculty Robert E. Hughes, PhD, expands knowledge of Huntington’s disease pathology and therapeutic targets

January 15, 2015/Novato CA. A study led by Buck faculty Robert E. Hughes, PhD, has been singled out by the Journal of Biological Chemistry (JBC) as one of the best papers published in 2014. The editors of JBC selected only 21 papers for this distinction from the thousands that were published that year. The Hughes study identified and analyzed thousands of protein interactions involving huntingtin, the protein responsible for Huntington’s disease (HD). The editors of JBC deemed it best study representing JBC’s Molecular Bases of Disease Affinity Group. It was published on March 7, 2014.

HD is an incurable, fatal, inherited neurological disorder that causes severe degeneration of the nervous system.  It is caused by a mutation in the human HTT gene that results in an abnormal expansion and misfolding of the corresponding huntingtin protein. Buck researchers established an unprecedented large-scale interaction network for the huntingtin protein identifying 2,141 highly interconnected proteins that have over 3,200 interactions among them.

Hughes used the analogy of a human social network to describe the work, “The identified proteins are like ‘friends’ and ‘friends of friends’ of the HD protein,” he said. “The network provides an invaluable resource for identifying targets to treat the disease and, in addition, has been used to implicate a particular signaling pathway involved in cell motility.”

The work results from a close collaboration between Buck faculty members Robert E. Hughes, PhD, an expert in neurodegeneration, and Sean D. Mooney, PhD, who leads the Institute’s bioinformatics program.  Researchers analyzed protein interaction data generated at Prolexys Pharmaceuticals that identified more than 100 huntingtin interacting proteins (HIPs) and more than 2,000 proteins that interact with HIPs.   “The damage caused by the mutant huntingtin protein radiates out through the cell, like ripples from a pebble dropped in a pond. In this case, the pond is filled with proteins that make up much of the cell,” said Hughes. “We now have a handle on the detailed structure of a complex web of interactions that can propagate global dysfunction in cells resulting in degeneration of the brain.”

In collaboration with Hughes, Mooney employed sophisticated computational methods which allowed researchers to comprehensively analyze the functions or so-called “jobs” of the proteins and networks and how they might be impacted by the huntingtin mutation. The investigators identified biological pathways that were enriched in the network.  In particular, HD mutations impacting the RhoGTPase signaling pathway interfered with filopodia, the slender projections that cells use to direct movement and communicate with other cells. The data indicate that the HD mutation directly affects membrane dynamics, cell attachment and cell motility. Defects in these pathways can provide critical clues for how to best intervene in the disease with drugs.

Highlighting the collaboration, Hughes said, “This study demonstrates how the synergy between experimental and computational approaches can help unravel the nature of a complex disease such as HD.” Mooney added, “Understanding and characterizing potentially functional HD protein interactions gives scientists new tools to connect genomic, genetic, proteomic and other molecular changes to identify the causes of this deadly disease.  Bioinformaticians can add this dataset to their systems biology toolbox in the quest for interventions that can suppress the progression of HD.”

Citation:   Tourette C, Li B, Bell R, O'Hare S, Kaltenbach LS, Mooney SD, Hughes RE. A Large-scale Huntingtin Protein Interaction Network Implicates Rho GTPase Signaling Pathways in Huntington's Disease. Journal of Biological Chemistry; Vol. 289, issue 10;  PubMed PMID: 24407293.

Other Buck Institute researchers contributing to the study include Cendrine Tourette, Biao Li, and Shannon O’Hare.  Other contributors include Russell Bell and Linda S. Kaltenbach,  Prolexys Pharmaceuticals, Salt Lake City, UT. The work was supported by the National Institutes of Health (NS 055247, GM084432, LM009722), The National Center for Biomedical Ontology (U54-HG004028) and the CHDI Foundation, Inc.

About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke.  In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information: www.thebuck.org

Share:
Change text size:
smaller

default

bigger